Diş Hekimliği Alanında Multipl Miyelom

Parker SL, Davis KJ, Wingo PA, et al. Cancer Statistics by Race and Ethnicity. A Cancer J Clin 1998; 48: 31–48.

Özkocaman Vi̇. Miyelom Kemik Hastalığı. HematoLog 2013; 3: 135–147.

Terpos E, Dimopoulos M. Myeloma bone disease : pathophysiology and management. 2005; 1223–1231.

Terpos E, Berenson J, Raje N, et al. Management of bone disease in multiple myeloma. Expert Rev Hematol 2014; 7: 113–125.

Durie BGM. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115: 522.

Gridelli C. The Use of Bisphosphonates in Elderly Cancer Patients. Oncologist 2007; 12: 62–71.

Croucher PI. Bone Disease in Multiple Myeloma. Br J Haematol 1998; 103: 902–910.

Almeida TMX de, Cavalcanti ÉFF, Freitas A da S, et al. Can dentists detect multiple myeloma through oral manifestations? Hematol Transfus Cell Ther 2018; 40: 43–49.

Shah A, Latoo S, Ahmad I. Multiple myeloma and dentistry. Mult Myeloma-An Overv.

Pinto LSS, Campagnoli EB, Leon JE, et al. Maxillary lesion presenting as a first sign of multiple myeloma: case report. Med Oral, Patol Oral y Cirugía Bucal 2007; 12: 344–347.

Mozaffari E, Mupparapu M, Otis L. Undiagnosed multiple myeloma causing extensive dental bleeding: report of a case and review. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology 2002; 94: 448–453.

Okay E. Bone Pathology in Multiple Myeloma: Diagnosis and Treatment. BOĞAZİÇİ TiDergi̇si̇ 2020; 7: 70–74.

Najeeb S, Zafar MS, Khurshid Z, et al. Bisphosphonate releasing dental implant surface coatings and osseointegration: A systematic review. J Taibah Univ Med Sci 2017; 12: 369–375.

Yi JW, Lee W, Kim S, et al. Effect of Zoledronate on the Expression of Vascular Endothelial Growth Factor-A by Articular Chondrocytes and Synovial Cells : An in Vitro Study. J Bone Metab 2014; 21: 249–255.

Bedogni A, Bettini G, Totola A, et al. Oral Bisphosphonate – Associated Osteonecrosis of the Jaw After Implant Surgery : A Case Report. J Oral Maxillofac Surg 2010; 68: 1662–1666.

Rugani P, Acham S, Truschnegg A. Bisphosphonate-associated osteonecrosis of the jaws : surgical treatment with ErCrYSGG-laser . Case report. YMOE 2010; 110: e1–e6.

Peer A, Khamaisi M. Diabetes as a Risk Factor for Medication-Related OSteonecrosis of the Jaw. J Dent Res 2014; 94: 252–260.

Allen MR, Burr DB. The Pathogenesis of Bisphosphonate- Related Osteonecrosis of the Jaw : So Many Hypotheses , So Few Data. YJOMS 2009; 67: 61–70.

Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw : incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. 2010; 181–188.

Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 2014; 72: 1938–1956.

Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81: 1047–1053.

Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw. Cancer Treat Rev 2015; 41: 455–464.

Saad F, Brown J, Van Poznak C, et al. of the jaw : integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341–1347.

Bodem JP, Kargus S, Engel M, et al. Value of nonsurgical therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw. J Cranio-Maxillofacial Surg 2015; 43: 1139–1143.

Campisi G, Fede O Di, Musciotto A, et al. Bisphosphonate-related osteonecrosis of the jaw ( BRONJ ): run dental management designs and issues in diagnosis. 2007; 18: 168–172.

Diel JI, Fogelman I, Al-Nawas B, et al. Pathophysiology , risk factors and management of bisphosphonate-associated osteonecrosis of the jaw : Is there a diverse relationship of amino- and. 2007; 64: 198–207.

Demirtaş N, Aytuğar E, Kazancıoğlu HO, et al. Multiple myelomalı hastada dental yaklaşım: olgu sunumu. Atatürk Üniversitesi Diş Hekim Fakültesi Derg 2015; 10: 46–50.

Şahin O, Tatar B, Ekmekcioğlu C, et al. Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution’s experience. J Clin Exp Dent 2020; 12: e771–e776.

Inchingolo AM, Malcangi G, Ferrara I, et al. MRONJ Treatment Strategies: A Systematic Review and Two Case Reports. Appl Sci; 13. Epub ahead of print 2023. DOI: 10.3390/app13074370.

Şahin O, Akan E, Tatar B, et al. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Braz J Otorhinolaryngol 2022; 88: 613–620.

Goker F, Grecchi E, Grecchi F, et al. Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review. Eur Rev Med Pharmacol Sci 2021; 25: 2662–2673.